SCHEMBL2333903

SCHEMBL2333903

[CH2]C(OCCC)OCCC

nearest known ligand 0.32

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
THRB P10828 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8435307 0.91
SCHEMBL8478252 0.89 ADRB2 (0.38)
SCHEMBL27475653 0.87 DNM1 (0.45) THRB
SCHEMBL8436246 0.85
SCHEMBL27471804 0.84 DNM1 (0.48) THRB
SCHEMBL8437652 0.84 HSD17B10 (0.34) HSD17B10TDP1
SCHEMBL1527700 0.81 ADRB2 (0.41) THRB
SCHEMBL8436735 0.81 HSD17B10 (0.31) HSD17B10TDP1
SCHEMBL4380234 0.80
SCHEMBL6179383 0.79 DNM1 (0.48) THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10201617-B2 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2019-02-12 US disclosed
US-9962452-B2 Soluble complexes of drug analogs and albumin ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2018-05-08 US disclosed
US-9937259-B2 Abiraterone derivatives and non-covalent complexes with albumin ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2018-04-10 US disclosed
US-20170319708-A1 3-Substituted Piperidine-2, 6-Diones and Non-Covalent Complexes with Albumin ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2017-11-09 US disclosed
US-20170216443-A1 ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2017-08-03 US disclosed
WO-2015200837-A1 ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN FL THERAPEUTICS LLC (US) 2015-12-30 WO disclosed
US-20150366984-A1 SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN ZHUHAI BEIHAI BIOTECH CO., LTD. (CN) 2015-12-24 US disclosed
US-9150585-B2 Analogs of camptothecin FL THERAPEUTICS LLC (US) 2015-10-06 US disclosed
WO-2014121033-A1 SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN FL THERAPEUTICS LLC (US) 2014-08-07 WO disclosed
US-20140135356-A1 Novel Analogs of Camptothecin FL Therapeutics, LLC (US) 2014-05-15 US disclosed
EP-0757682-A1 BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-02-12 EP disclosed
WO-1996034866-A1 IMIDAZO 1,2-A PYRIDINE AND IMIDAZO 1,2-A PYRIDEZINE DERIVATIVES AND THEIR USE AS BONE RESORPTION INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-11-07 WO disclosed
WO-1996005179-A1 SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS BASF AKTIENGESELLSCHAFT (DE) 1996-02-22 WO disclosed
WO-1995029907-A1 BENZOFURAN DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-11-09 WO disclosed
WO-1994011344-A1 SUBSTITUTED 3,4,5,6-TETRAHYDROPHTHALIMIDES FOR USE AS HERBICIDES AND/OR DEFOLIANTS OR DESICCANTS BASF AKTIENGESELLSCHAFT (DE) 1994-05-26 WO disclosed
EP-0137145-B1 NEW CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME KABUSHIKI KAISHA YAKULT HONSHA (JP) 1988-04-27 EP disclosed
US-4604463-A ANTITUMOR AGENTS KABUSHIKI KAISHA YAKULT HONSHA (JP) 1986-08-05 US disclosed
EP-0137145-A1 New camptothecin derivatives and process for preparing same KABUSHIKI KAISHA YAKULT HONSHA (JP) 1985-04-17 EP disclosed
US-4127720-A ANTIALLERGENS BRISTOL-MYERS COMPANY (US) 1978-11-28 US disclosed
US-4053318-A SENSITIZING MEROCYANINE DYE FUJI PHOTO FILM CO., LTD. (JA) 1977-10-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140135356-A1 Novel Analogs of Camptothecin DCLRE1A, PAICS, TOP2A HSD17B10 1174/4885TDP1 517/4885THRB 1940/4885
US-20170216443-A1 ABIRATERONE DERIVATIVES AND NON-COVALENT COMPLEXES WITH ALBUMIN CYP17A1, SHBG, CYP19A1 HSD17B10 27/4885TDP1 2148/4885THRB 4584/4885
US-10201617-B2 3-substituted piperidine-2, 6-diones and non-covalent complexes with albumin ALB, BCL9, CD2BP2 HSD17B10 4714/4885TDP1 3729/4885THRB 4774/4885
US-20170319708-A1 3-Substituted Piperidine-2, 6-Diones and Non-Covalent Complexes with Albumin ALB, BCL9, CD2BP2 HSD17B10 4714/4885TDP1 3729/4885THRB 4774/4885
US-20150366984-A1 SOLUBLE COMPLEXES OF DRUG ANALOGS AND ALBUMIN ALB, TP53, HMGB1 HSD17B10 3395/4885TDP1 3358/4885THRB 4181/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.